LenioBio GmbH

LenioBio has received CEPI (Coalition for Epidemic Preparedness Innovations) funding of up to US $2 million to provide preclinical proof-of-concept that their commercially available, plant-based, and cell-free technology can produce proteins for use in clinical trials testing vaccines against epidemic and pandemic threats in 20-40 days. This animation visualizes the mini-protoplast containing the concentrated protein production machinery of the living cell. We offer an end-to-end protein service for research-grade protein expression. We believe that everyone deserves an equal chance to lead a healthy life. To simplify biomanufacturing and speed up the delivery of drugs to the patient. Plant-based ALiCE technology could shave weeks off vaccine production. In our latest publication in the Journal of Biotechnology and Bioengineering, we describe the production and functional analysis of complex proteins using ALiCE, and showcase scaling in the system – a first for eukaryotic cell-free.